PET imaging of mGluR5 with drug challenge

Diseases and Conditions Researched

Major Depressive Disorder

What is the purpose of this trial?

This study is designed to look at that involvement of a process in the brain called the glutamate system in depression. Participants will undergo a screening session, up to two fMRI scans, and up to three PET scans, as well as cognitive testing at each scan session. For one of the PET scans, a drug (either ketamine or n-acetyl cysteine) will be administered.

Hypothesis 1: The investigators hypothesize administration of ketamine or n-acetylcysteine (NAC) will lead to a decrease in mGluR5.

Hypothesis 2: The investigators hypothesize an improvement in memory and attentional skills after drug challenge.

Hypothesis 3: The investigators hypothesize an increase in mGluR5 availability and change in MRI measures post drug challenge as compared to baseline, signifying synaptogenesis.

Participation Guidelines

Age: 18 Years - 65 Years
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: National Institutes of Health
Last Updated:
Study HIC#: 1111009365